0001493152-22-008503.txt : 20220331 0001493152-22-008503.hdr.sgml : 20220331 20220331163723 ACCESSION NUMBER: 0001493152-22-008503 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220331 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220331 DATE AS OF CHANGE: 20220331 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INTERPACE BIOSCIENCES, INC. CENTRAL INDEX KEY: 0001054102 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 222919486 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-24249 FILM NUMBER: 22793341 BUSINESS ADDRESS: STREET 1: MORRIS CORPORATE CENTER 1, STREET 2: BUILDING C, 300 INTERPACE PARKWAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 BUSINESS PHONE: 412-224-6100 MAIL ADDRESS: STREET 1: MORRIS CORPORATE CENTER 1, STREET 2: BUILDING C, 300 INTERPACE PARKWAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 FORMER COMPANY: FORMER CONFORMED NAME: Interpace Diagnostics Group, Inc. DATE OF NAME CHANGE: 20151223 FORMER COMPANY: FORMER CONFORMED NAME: PDI INC DATE OF NAME CHANGE: 20021113 FORMER COMPANY: FORMER CONFORMED NAME: PROFESSIONAL DETAILING INC DATE OF NAME CHANGE: 19980129 8-K 1 form8k.htm
0001054102 false 0001054102 2022-03-31 2022-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): March 31, 2022

 

INTERPACE BIOSCIENCES, INC.

(Exact name of Registrant as specified in its charter)

 

delaware   0-24249   22-2919486

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

Morris Corporate Center 1, Building C

300 Interpace Parkway,

Parsippany, NJ 07054

(Address, including zip code, of Principal Executive Offices)

 

(855) 776-6419

Registrant’s telephone number, including area code

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
None   N/A   N/A

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

☐ Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 2.02 Results of Operations and Financial Condition.

 

On March 31, 2022, Interpace Biosciences, Inc. issued a press release announcing its results of operations and financial condition for the fiscal year ended December 31, 2021. The full text of the press release is set forth as Exhibit 99.1 attached hereto and is incorporated herein by reference.

 

The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit Number   Description
     
99.1   Press Release, dated March 31, 2022
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Interpace Biosciences, Inc.
     
  By: /s/ Thomas W. Burnell
  Name: Thomas W. Burnell
  Title: President and Chief Executive Officer

 

Date: March 31, 2022

 

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 

Interpace Biosciences Announces Full Year and Fourth Quarter 2021 Financial and Business Results

 

  ● 2021 Full Year Net Revenue of $41.3 Million up 28% vs Prior Year; Fourth Quarter Net Revenue of $10.9 Million up 13% vs Prior Year
  ● 2021 Full Year Net Loss Improved $11.5 Million vs Prior Year
  ● Full year Cash Collections improved by 31% to $43.1 million and outpaced Revenue by nearly $2 million

 

PARSIPPANY, NJ, March 31, 2022 (GLOBE NEWSWIRE) —Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fiscal year and fourth quarter ended December 31, 2021 and provided a business and financial update.

 

“2021 has been a transformative year for Interpace,” said Thomas Burnell, President and CEO. Burnell added, “The Company established a sense of urgency and focus, right-sized its infrastructure, forged significant lending and investor relationships, and markedly grew revenue and improved overall profitability despite many unanticipated challenges.”

 

Thomas Freeburg, the Company’s CFO added, “During 2021, Interpace achieved significant improvement in overall profitability compared to the prior two successive years, with improved financial results across the board. We achieved substantial revenue growth and gross margin expansion while significantly reducing operating expenses. We intend to continue our focus on expense control, revenue growth, commercial payer reimbursement and expansion to drive further improvement in our profitability in 2022.”

 

Burnell continued, “While we did not fully achieve our lofty expectations of being cash flow breakeven by the end of 2021, and we entered 2022 with concerns related to reimbursement of the Company’s flagship Thyroid test, ThyGENext®, we have been notified by Centers for Medicare & Medicaid Services (CMS) and National Correct Coding Initiative (NCCI) that processing of claims for dates of service after January 1, 2022 will be completed beginning July 1, 2022 and are prepared to move forward with our planned growth strategy – with emphasis on expansion of the Company’s clinical diagnostics testing platform and portfolio, and a streamlined, more efficient approach to meeting the needs of our pharma services clients.”

 

Full-Year 2021 Financial Performance as Compared to Full-Year 2020

 

  ● Net Revenue was $41.3 million, an increase of 28% versus the prior year. The increase in Net Revenue was driven by increased reimbursement rates and clinical services volume, partially offset by a decrease in pharma services revenue.
     
  ● Gross Profit percentage was 43% compared to 33% for the prior year, a 1,000 basis-point improvement year over year. The Gross Profit improvement can be attributed to the increased reimbursement rates as well as a greater mix of proprietary molecular diagnostic tests.
     
  ●

Loss from Continuing Operations was $(14.7) million vs $(26.2) million in the prior year. Net loss was $(14.9) million compared to $(26.5) million in the prior year.

 

 

 

 

  ● Adjusted EBITDA was $(5.1) million as compared to $(15.4) million for the prior year. The improvement is primarily attributable to the lower Loss from Continuing Operations.
     
  ● Full year Cash collections improved by 31% to $43.1 million and outpaced revenue by nearly $2 million. Days Sales Outstanding (DSO) decreased 40% year over year to 54 days.
     
  ● December 31, 2020 cash balance was $2.8 million, net of restricted cash. December 31, 2021 cash balance was $3.1 million, net of restricted cash.

 

Fourth Quarter 2021 Financial Performance as Compared to the Fourth Quarter of 2020

 

  ●

Net Revenue was $10.9 million for the fourth quarter of 2021, a 13% improvement over the prior year period. The increase in Net Revenue was driven by increased reimbursement rates and clinical services volume, partially offset by a decrease in pharma services revenue.

 

  ● Gross Profit percentage was 41% compared to 32% for the fourth quarter of 2020, with the improvement driven by higher volume, increases in reimbursement rates and a change in the gross profit mix.
     
  ● Loss from Continuing Operations was $(3.7) million vs $(8.1) million in the prior year quarter, an improvement of $4.4 million.
     
  ● Adjusted EBITDA was $(2.1) million vs $(4.1) million in the prior year quarter, with the improvement primarily attributable to the lower Loss from Continuing Operations.

 

Recent Highlights

 

  ● In January 2022, we announced the appointment of Vijay Aggarwal, Ph.D. to the Board of Directors effective February 1, 2022, replacing Eric B. Lev. Dr. Aggarwal and Mr. Lev were each designees of Ampersand 2018 Limited Partnership, a Series B Preferred stockholder of the Company.
     
  ● In January 2022, the Company announced that CMS issued a new billing policy whereby CMS will no longer reimburse for the use of the Company’s ThyGeNEXT® and ThyraMIR® tests when billed together by the same provider/supplier for the same beneficiary on the same date of service. On February 28, 2022, the Company announced that the National Correct Coding Initiative (NCCI) program issued a response on behalf of CMS stating that the January 2022 billing policy reimbursement change for ThyGeNEXT® (0245U) and ThyraMIR® (0018U) tests has been retroactively reversed to January 1, 2022. CMS is currently reimbursing the Company for one of its two thyroid tests, and has agreed to retroactively reimburse for the second test once they have completed their internal administrative adjustments, confirming their acknowledgment that all tests will be reimbursed retroactive to January 1, 2022. As of the date of this filing, the Company has not yet realized the full cash collection benefit of current and retroactive Thyroid testing and such cash collections may be temporarily reduced or delayed until we resolve the matter with CMS.
     
  ● During the fourth quarter of Fiscal 2021, the Company expanded commercial payor coverage of its proprietary Thyroid tests adding one new in-network contract. With the contracts added earlier in the year, Interpace now has contracts with 55 commercial payors.

 

 

 

 

About Interpace Biosciences

 

Interpace Biosciences is an emerging leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.

 

Clinical services, through Interpace Diagnostics, provides clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has five commercialized molecular tests and one test in a clinical evaluation program (CEP): PancraGEN® for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; PanDNA, a “molecular only” version of PancraGEN® that provides physicians a snapshot of a limited number of factors; ThyGeNEXT® for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; ThyraMIR® for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and RespriDX® that differentiates lung cancer of primary versus metastatic origin and for which the Company only has nominal revenues. In addition, BarreGEN®, a molecular based assay that helps resolve the risk of progression of Barrett’s Esophagus to esophageal cancer, is currently in a clinical evaluation program (CEP) whereby we gather information from physicians using BarreGEN® to assist us in gathering clinical evidence relative to the safety and performance of the test and also providing data that will potentially support payer reimbursement.

 

Pharma services, through Interpace Pharma Solutions, provides pharmacogenomics testing, genotyping, biorepository and other customized services to the pharmaceutical and biotech industries. Pharma services also advances personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goals of delivering safer, more effective drugs to market more quickly, while also improving patient care.

 

For more information, please visit Interpace Biosciences’ website at www.interpace.com.

 

 

Forward-looking Statements

 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company’s future financial and operating performance. The Company has attempted to identify forward looking statements by terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company’s control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from those expressed or implied by any forward-looking statements including, but not limited to, the adverse impact of the COVID-19 pandemic on the Company’s operations and revenues, the substantial doubt about the Company’s ability to continue as a going concern, the possibility that the Company’s estimates of future revenue, cash flows and adjusted EBITDA may prove to be materially inaccurate, the Company’s history of operating losses, the Company’s ability to adequately finance its business, the Company’s ability to repay borrowings under its $7.5M credit facility with Comerica Bank and its $8M term loan with BroadOak, the Company’s dependence on sales and reimbursements from its clinical services, the Company’s ability to retain or secure reimbursement including its reliance on third parties to process and transmit claims to payers and the adverse impact of any delay, data loss, or other disruption in processing or transmitting such claims, and the Company’s revenue recognition being based in part on estimates for future collections which estimates may prove to be incorrect. Additionally, all forward-looking statements are subject to the “Risk Factors” detailed from time to time in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as amended, Current Reports on Form 8-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

 

Contacts:

 

Investor Relations

Interpace Biosciences, Inc.

(855)-776-6419

Info@Interpace.com

 

 

 

 

INTERPACE BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)

 

   Three Months Ended   Years Ended 
   December 31,   December 31, 
   2021   2020   2021   2020 
   (unaudited)         
Revenue, net  $10,853   $9,646   $41,314   $32,398 
Cost of revenue   6,404    6,517    23,369    21,673 
Gross Profit   4,449    3,129    17,945    10,725 
                     
Sales and marketing   2,482    2,478    10,067    9,254 
Research and development   407    673    1,882    2,795 
General and administrative   4,030    5,508    13,669    18,192 
Transition expenses   111    1,780    2,585    2,578 
Loss on DiamiR transaction   248    -    13    - 
Acquisition amortization expense   728    1,115    4,064    4,461 
Change in fair value of contingent consideration   (281)   (489)   (338)   (489)
Total operating expenses   7,725    11,065    31,942    36,791 
                     
Operating loss   (3,276)   (7,936)   (13,997)   (26,066)
Interest accretion expense   (121)   (135)   (496)   (549)
Related party interest   (52)   -    (424)   - 
Other (expense) income, net   (241)   (6)   (496)   467 
Loss from continuing operations before tax   (3,690)   (8,077)   (15,413)   (26,148)
Provision (benefit) for income taxes   17    10    (667)   53 
Loss from continuing operations   (3,707)   (8,087)   (14,746)   (26,201)
                     
Loss from discontinued operations, net of tax   (22)   (56)   (197)   (250)
                     
Net loss   (3,729)   (8,143)   (14,943)   (26,451)
                     
Less adjustment for preferred stock deemed dividend   -    -    -    (3,033)
                     
Net loss attributable to common stockholders  $(3,729)  $(8,143)  $(14,943)  $(29,484)
                     
Basic and diluted loss per share of common stock:                    
From continuing operations  $(0.89)  $(2.00)  $(3.57)  $(7.26)
From discontinued operations   -    (0.01)   (0.04)   (0.06)
Net loss per basic share of common stock  $(0.89)  $(2.01)  $(3.61)  $(7.32)
                     
Weighted average number of common shares and                    
common share equivalents outstanding:                    
Basic   4,181    4,043    4,135    4,029 
Diluted   4,181    4,043    4,135    4,029 

 

 

 

 

Selected Balance Sheet Data

($ in thousands)

 

   December 31,   December 31, 
   2021   2020 
         
Cash, cash equivalents and restricted cash  $3,314   $3,372 
           
Total current assets   12,166    14,122 
Total current liabilities   15,682    18,233 
           
Total assets   38,427    45,681 
Total liabilities   34,309    28,228 
Total stockholders’ deficit   (42,418)   (29,083)

 

Selected Cash Flow Data

($ in thousands)

 

   For the Years Ended 
   December 31, 
   2021   2020 
Net loss  $(14,943)  $(26,451)
           
Net cash used in operating activities  $(8,719)  $(13,979)
Net cash used in investing activities   (315)   (1,575)
Net cash provided by financing activities   8,976    16,605 
Change in cash, cash equivalents and restricted cash   (58)   1,051 
Cash, cash equivalents and restricted cash – beginning   3,372    2,321 
Cash, cash equivalents and restricted cash – ending  $3,314   $3,372 
           

 

 

 

 

Reconciliation of Adjusted EBITDA (Unaudited)

($ in thousands)

 

   Three Months Ended   Years Ended 
   December 31,   December 31, 
   2021   2020   2021   2020 
Loss from continuing operations (GAAP Basis)  $(3,707)  $(8,087)  $(14,746)  $(26,201)
Bad debt (recovery) expense   -    335    (140)   585 
Loss on DiamiR transaction   248    -    13    - 
Receipt of HHS stimulus grant   -    -    -    (650)
Transition expenses   111    1,780    2,585    2,578 
Legal and professional services   -    -    -    495 
Depreciation and amortization   1,024    1,399    5,374    5,501 
Stock-based compensation   54    861    1,368    2,242 
Taxes expense(benefit)   17    10    (667)   53 
Interest accretion expense   121    135    496    549 
Financing interest and related costs   468    -    950    - 
Mark to market on warrant liability   (87)   1    50    (61)
Change in fair value of note payable   (58)   -    (58)   - 
Change in fair value of contingent consideration   (281)   (489)   (338)   (489)
Adjusted EBITDA  $(2,090)  $(4,055)  $(5,113)  $(15,398)

 

Non-GAAP Financial Measures

 

In addition to the United States generally accepted accounting principles, or GAAP, results provided throughout this document, we have provided certain non-GAAP financial measures to help evaluate the results of our performance. We believe that these non-GAAP financial measures, when presented in conjunction with comparable GAAP financial measures, are useful to both management and investors in analyzing our ongoing business and operating performance. We believe that providing the non-GAAP information to investors, in addition to the GAAP presentation, allows investors to view our financial results in the way that management views financial results.

 

In this document, we discuss Adjusted EBITDA, a non-GAAP financial measure. Adjusted EBITDA is a metric used by management to measure cash flow of the ongoing business. Adjusted EBITDA is defined as income or loss from continuing operations, plus depreciation and amortization, acquisition related expenses, transition expenses, non-cash stock based compensation and ESPP plans, interest and taxes, and other non-cash expenses including asset impairment costs, bad debt expense, receipt of stimulus grants, loss on extinguishment of debt, goodwill impairment and change in fair value of contingent consideration, and warrant liability. The table above includes a reconciliation of this non-GAAP financial measure to the most directly comparable GAAP financial measure.

 

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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idxg-20220331.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 idxg-20220331_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Entity Information, Former Legal or Registered Name EX-101.PRE 6 idxg-20220331_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover
Mar. 31, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 31, 2022
Entity File Number 0-24249
Entity Registrant Name INTERPACE BIOSCIENCES, INC.
Entity Central Index Key 0001054102
Entity Tax Identification Number 22-2919486
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One Morris Corporate Center 1
Entity Address, Address Line Two Building C
Entity Address, Address Line Three 300 Interpace Parkway
Entity Address, City or Town Parsippany
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07054
City Area Code (855)
Local Phone Number 776-6419
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Information, Former Legal or Registered Name Not Applicable
XML 8 form8k_htm.xml IDEA: XBRL DOCUMENT 0001054102 2022-03-31 2022-03-31 iso4217:USD shares iso4217:USD shares 0001054102 false 8-K 2022-03-31 INTERPACE BIOSCIENCES, INC. DE 0-24249 22-2919486 Morris Corporate Center 1 Building C 300 Interpace Parkway Parsippany NJ 07054 (855) 776-6419 Not Applicable false false false false false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://interpace.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8k.htm ex99-1.htm idxg-20220331.xsd idxg-20220331_lab.xml idxg-20220331_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "form8k.htm" ] }, "labelLink": { "local": [ "idxg-20220331_lab.xml" ] }, "presentationLink": { "local": [ "idxg-20220331_pre.xml" ] }, "schema": { "local": [ "idxg-20220331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 60, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "IDXG", "nsuri": "http://interpace.com/20220331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8k.htm", "contextRef": "From2022-03-31to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://interpace.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8k.htm", "contextRef": "From2022-03-31to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationFormerLegalOrRegisteredName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Legal or Registered Name of an entity", "label": "Entity Information, Former Legal or Registered Name" } } }, "localname": "EntityInformationFormerLegalOrRegisteredName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interpace.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 15 0001493152-22-008503-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-008503-xbrl.zip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end